300439 Stock Overview
Provides clinical diagnostics reagents and instruments in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Medicalsystem Biotechnology Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.54 |
| 52 Week High | CN¥13.24 |
| 52 Week Low | CN¥7.28 |
| Beta | 0.39 |
| 11 Month Change | 1.14% |
| 3 Month Change | 28.94% |
| 1 Year Change | -5.56% |
| 33 Year Change | -48.89% |
| 5 Year Change | -13.88% |
| Change since IPO | -65.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300439 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 6.3% | -2.6% | -2.1% |
| 1Y | -5.6% | -20.9% | 2.8% |
Return vs Industry: 300439 exceeded the CN Biotechs industry which returned -20.9% over the past year.
Return vs Market: 300439 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 300439 volatility | |
|---|---|
| 300439 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300439 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300439's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,164 | Ji Hua Zou | www.nbmksw.com |
Medicalsystem Biotechnology Co., Ltd. provides clinical diagnostics reagents and instruments in China. The company offers automated biochemistry analyzers and bio reagents; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; and glycated hemoglobin analyzer, blood lipid analyzer, POCT, microfluidic biochemical analyzer. The company also provides urine analyzers, urine sediment analyzers; PCR kit, antibody test kit, antigen and antibody test kit, and nucleic acid reagent for COVID-19.
Medicalsystem Biotechnology Co., Ltd Fundamentals Summary
| 300439 fundamental statistics | |
|---|---|
| Market cap | CN¥4.43b |
| Earnings (TTM) | CN¥250.96m |
| Revenue (TTM) | CN¥1.82b |
17.7x
P/E Ratio2.4x
P/S RatioIs 300439 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300439 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.82b |
| Cost of Revenue | CN¥1.00b |
| Gross Profit | CN¥818.58m |
| Other Expenses | CN¥567.62m |
| Earnings | CN¥250.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 44.93% |
| Net Profit Margin | 13.77% |
| Debt/Equity Ratio | 1.4% |
How did 300439 perform over the long term?
See historical performance and comparison